Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q2 FY2022 Earnings Presentation
25 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, November 2021
Slide 1: IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q2FY22
IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q2FY22 November 2021
Slide 2: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: About IOL Chemicals and Pharmaceuticals Limited
About IOL Chemicals and Pharmaceuticals Limited Incorporated in 1986, IOLCP is one of the leading Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Catering to the top-tier players across diverse important industries like pharmaceutic
Slide 4: Key Highlights
Key Highlights Team size of 2,200+ Largest producer of Largest producer of Ethyl 2nd Largest producer of Over 20 products are employees Ibuprofen and the only Acetate at Single Location Iso Butyl Benzene (IBB) commercialised with 8 company worldwide being in India with ~30% Global share products in
Slide 5: Professional Management Team
Professional Management Team Mr. Varinder is an industrialist and has wide and rich Mr. Vikas is academically equipped with the experience of more than 35 years in the chemical & knowledge and possesses organizational capacity. He fertilizer industry and along with a comprehensive has worked in stra
Slide 6: Experienced Independent Directors
Experienced Independent Directors Rajender Mohan Malla Dr. Sandhya Mehta Harpal Singh (Chairman and Independent (Independent Director) (Independent Director) Director) • Mr. Rajender has very distinguished career • Dr. Sandhya is working as the principal of • Mr. Harpal has had over 35 year's of fou
Slide 7: Our Journey
Our Journey Unit-3 Multi Unit 06- Pantoprazole Specialty Product 2016 2018 2019 2020 2021 Unit 04- Metformin Unit 07- Metformin Unit 8 & Unit 10 Multi Products 2012 Unit 02- Unit-5 Clopidogrel & Fenofibrate Ibuprofen (Dedicated) Unit 01- Ibuprofen (Dedicated) Cogeneration Plant- 4 MW 2010 2009 2007
Slide 8: Certifications and Accreditations
Certifications and Accreditations Approved USFDA Ibuprofen EUGMP Certification in Certificate of Suitability Certificate of Suitability facility since 2015, 2013, 2017 & from EDQM for from EDQM for recertified in 2019 Recertification in 2020 IBUPROFEN, CEP No. 316- LAMOTRIGINE, CEP No. 2008 066-2013
Slide 9: Product Segmentation
Product Segmentation 9
Slide 10: Business Segment – Pharmaceuticals
Business Segment – Pharmaceuticals IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen Among the largest Added more than 8 new Product portfolio that producer of Metfor
Slide 11: Pharmaceuticals Product Portfolio – Commercialized & Pipeline
Pharmaceuticals Product Portfolio – Commercialized & Pipeline API - Commercialized API - Pipeline Ibuprofen Fexofenadine Ibuprofen Lysinate Quetiapine Fumarate Ibuprofen Sodium Dex-Ibuprofen Dextromethorphan Metformin HCL Apixaban Clopidogrel Bisulphate (Form II) Pantoprazole Sodium Alluprinol Fenof
Slide 12: Business Segment – Specialty Chemicals
Business Segment – Specialty Chemicals IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 tonnes per annum. Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 100,000 tonnes per annum
Slide 13: Product wise Segmentation – Quarterly
Product wise Segmentation – Quarterly Q2FY22 Q1FY22 Q2FY21 15% 12% 9% 37% 56% 29% 29% 59% 54% Other Pharma Chemicals Ibuprofen Products 13 All figures in INR crs unless stated
Slide 14: Product wise Segmentation – Half Yearly
Product wise Segmentation – Half Yearly H1FY22 H1FY21 14% 9% 35% 57% 29% 56% Other Pharma Chemicals Ibuprofen Products 14 All figures in INR crs unless stated
Slide 15: Manufacturing Facility spread across over 111 acres with GMP approved guidelines
Manufacturing Facility spread across over 111 acres with GMP approved guidelines API manufactured in batch manner and Facility is coupled with ISO class-8 HVAC intermediates & Specialty chemicals in Dedicated blocks involved in manufacturing system, PSA Nitrogen & Purified water along continuous pro
Slide 16: Our Core Sustainability Pillars
Our Core Sustainability Pillars • Strive to minimize the adverse impact on • Construction and renovation of school locations, environment, health and Safety by upgrading provided technical equipment for smart education technology, optimum utilization of resources and • Primary healthcare including s
Slide 17: Financial Overview
Financial Overview 17
Slide 18: Key Financial Summary
Key Financial Summary Financial Summary Q2FY22 Q1FY22 Q2FY21 H1FY22 H1FY21 (INR Cr) Total Income 548 524 538 1,073 1,004 Gross Profit 143 189 247 332 465 EBITDA 54 116 176 170 333 PAT 31 67 127 98 255 18 All Profits and Total Income include Other Income
Slide 19: 5 years Financial Performance - Annually
5 years Financial Performance - Annually Revenues & Margins* – Annual Margin* Expansion – Over the Years 2,000 1,910 1,991 50% 50% Gross % 1,800 1,696 45% 45% 45% 45% 12% 1,600 44% 40% 40% EBITDA % 1,400 33% 38% 31% 31% 35% 35% 33% 30% 31% 1,200 25% 30% 30% 16% 990 22% PAT % 22% 1,000 25% 25% 19% 80
Slide 20: Quarterly & Half Yearly Financial Performance
Quarterly & Half Yearly Financial Performance Quarterly Revenues & Margins* Half Yearly Revenues & Margins* 560 46% 50% 1,100 46% 1,073 50% 36% 548 550 33% 40% 33% 40% 26% 1,050 540 538 30% 31% 30% 22% 25% 530 24% 524 20% 1,004 16% 20% 10% 1,000 520 10% 10% 13% 6% 9% 510 0% 950 0% Q2FY21 Q1FY22 Q2FY
Slide 21: Geographical Segmental Breakup – Annual, Half Year & Quarter
Geographical Segmental Breakup – Annual, Half Year & Quarter Annually Half Yearly Quarterly In INR crs In INR crs In INR crs 1,354 831 1,250 1,038 674 26% 435 30% 396 374 633 647 644 613 16% 484 319 350 225 159 142 227 83 FY17 FY18 FY19 FY20 FY21* H1FY22 H1FY21 Q2FY22 Q1FY22 Q2FY21 Domestic Export 2
Slide 22: Financial Summary – Balance Sheet
Financial Summary – Balance Sheet Balance Sheet (INR Crs) FY17 FY18 FY19 FY20 FY21 H1 FY22 Shareholder's Funds 188.7 215.7 474.3 813.5 1260.4 1345.4 Debt 446.5 421.9 284.0 56.0 0.0 0.0 Other Long Term Liabilities 17.2 33.6 20.8 79.7 59.1 59.0 Other Current Liabilities 165.1 180.9 162.8 220.6 290.6 3
Slide 23: Financial Summary – Statement of Profit and Loss
Financial Summary – Statement of Profit and Loss P&L (INR Crs) FY17 FY18 FY19 FY20 FY21 Q2FY22 Q1FY22 Q2FY21 H1FY22 H1FY21 Revenues 710.6 983.3 1,685.3 1,894.5 1,967.0 537.9 518.5 533.5 1,056.4 993.6 Other Income 1.3 6.3 10.4 16.0 24.3 10.5 5.7 4.5 16.2 10.3 Total Income 711.9 989.6 1,695.7 1,910.5
Slide 24: Shareholding Information
Shareholding Information Stock Data (As on 30th September, 2021) Shareholding Pattern (%) 53.2% Market Capitalization (₹) 3,484 Crs 49.9% 43.7% 43.7% Face Value(₹) 10 Share Price (₹) 593.5 EPS TTM (₹) 49.0 52-Week High (₹) 783.0 6.4% 3.1% 52-Week Low (₹) 516.3 Promoter Institutional Non-Institutiona
Slide 25: Thank You
Thank You For further details: Mr. Pardeep Kumar Khanna , CFO Email: pardeepkhanna@iolcp.com Phone: +91-161-2225531-35
IOL Chemicals and Pharmaceuticals — Q2 FY2022 Earnings Presentation on 6ix